Skip to content
Regen Biopharmainc

Menu

Regen Biopharmainc

Menu

Author: user

April 27, 2015 | SOURCE: REGEN BIOPHARMA, INC.

Regen BioPharma Sees Opportunities Resulting from AACR Conference Attendance and Presentation

April 22, 2015 | SOURCE: REGEN BIOPHARMA, INC.

Regen BioPharma, Inc. Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial

April 16, 2015 | SOURCE: REGEN BIOPHARMA, INC.

Regen BioPharma Recruits Renowned Cancer Stem Cell Experts to Scientific Advisory Board

April 13, 2015 | SOURCE: REGEN BIOPHARMA, INC.  

Regen BioPharma Narrows Selection of CRO Candidates for HemaXellerate GLP Safety Studies Requested by the FDA

April 9, 2015 | SOURCE: REGEN BIOPHARMA, INC.

Regen BioPharma Inc. Announces Small Molecule Drug Discovery Milestones at the American Association for Cancer Research’s 2015 Annual Meeting 

April 7, 2015 | SOURCE: REGEN BIOPHARMA, INC.  

Regen BioPharma Inc. to Present Multiple Presentations at the 13th International Symposium on Myelodysplastic Syndromes

April 6, 2015 | SOURCE: REGEN BIOPHARMA, INC.

Regen BioPharma Expands Its Differentiation Therapy of Cancer Stem Cells Platform With Filing of Patent Applications on Silencing of NR2F2 

April 1, 2015 | SOURCE: REGEN BIOPHARMA, INC.

Regen BioPharma CEO Discusses Recent Financings, New Laboratory Facilities and Preferred Stock Dividend 

March 31, 2015 | SOURCE: REGEN BIOPHARMA, INC.  

Regen BioPharma Announces Presentation of DiffronC at Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics

March 24, 2015 | SOURCE: REGEN BIOPHARMA, INC.

Regen BioPharma, Inc. Expands Research Capacity With New Laboratory Facilities 

← Previous
Next →
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

Quick Links

  • About Us
  • Product Pipeline
  • Investor Relations
  • News
  • Careers
  • Contact Us
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

Quick Links

  • About Us
  • Product Pipeline
  • Investor Relations
  • News
  • Careers
  • Contact Us
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

Quick Links

  • Home
  • About Us
  • Product Pipeline
  • Investor Relations
  • News
  • Careers
  • Contact Us
Back to top

© COPYRIGHT 2023. ALL RIGHTS RESERVED.

  • Terms Of Use
  • Accessibility
Twitter
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA. Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents
  • Terms Of Use
  • Accessibility

Quick Links

  • Home
  • About Us
  • Product Pipeline
  • News
  • Management Team
  • Investor Relations​
  • Contact Us
Back to top
  • Terms Of Use
  • Accessibility
Twitter

© COPYRIGHT 2023. ALL RIGHTS RESERVED.

  • Home
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates

An overview of Regen BioPharma

  • About Us​
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us

Our management, scientific advisory board and intellectual property

  • Product Pipeline
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC

Details around our intellectual property and its development

  • Investor Relations
  • Regulatory Filings
  • Regulatory Filings

Our public filing and stock information

  • Company News
  • Featured News
  • News and Updates
  • Featured News
  • News and Updates

Our press releases and upcoming events

  • Home

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • About Us​

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Investor Relations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Company News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Regulatory Filings
  • Regulatory Filings
  • Contact us
  • Careers
  • Press Releases
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
Twitter
Home

What we do

Product Pipeline

Investor Relations

News & Updates

About Us

Management Team and Scientific Advisory Board

Careers

Contact Us

Product Pipeline

DuraCAR

KimerApt

HemaXellerate

dCellVax

tCellVax

DiffronC

Investor Relations

Regulatory Filings

Company News

Featured News

News and Updates

  • Contact us
  • Careers
  • Press Releases
Twitter
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
  • Home
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates

An overview of Regen BioPharma

  • About Us​
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us

Our management, scientific advisory board and intellectual property

  • Product Pipeline
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC

Details around our intellectual property and its development

  • Investor Relations
  • Regulatory Filings
  • Regulatory Filings

Our public filing and stock information

  • Company News
  • Featured News
  • News and Updates
  • Featured News
  • News and Updates

Our press releases and upcoming events

  • Home

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • About Us​

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Investor Relations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Company News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Regulatory Filings
  • Regulatory Filings
  • Contact us
  • Careers
  • Press Releases
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
Twitter
Home

What we do

Product Pipeline

Investor Relations

News & Updates

About Us

Management Team and Scientific Advisory Board

Careers

Contact Us

Product Pipeline

DuraCAR

KimerApt

HemaXellerate

dCellVax

tCellVax

DiffronC

Investor Relations

Regulatory Filings

Company News

Featured News

News and Updates

  • Contact us
  • Careers
  • Press Releases
Twitter
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases